These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
203 related items for PubMed ID: 23285138
1. Alterations in glutathione levels and apoptotic regulators are associated with acquisition of arsenic trioxide resistance in multiple myeloma. Matulis SM, Morales AA, Yehiayan L, Lee KP, Cai Y, Boise LH. PLoS One; 2012; 7(12):e52662. PubMed ID: 23285138 [Abstract] [Full Text] [Related]
2. Darinaparsin induces a unique cellular response and is active in an arsenic trioxide-resistant myeloma cell line. Matulis SM, Morales AA, Yehiayan L, Croutch C, Gutman D, Cai Y, Lee KP, Boise LH. Mol Cancer Ther; 2009 May; 8(5):1197-206. PubMed ID: 19417148 [Abstract] [Full Text] [Related]
3. Ethacrynic acid and a derivative enhance apoptosis in arsenic trioxide-treated myeloid leukemia and lymphoma cells: the role of glutathione S-transferase p1-1. Wang R, Liu C, Xia L, Zhao G, Gabrilove J, Waxman S, Jing Y. Clin Cancer Res; 2012 Dec 15; 18(24):6690-701. PubMed ID: 23082001 [Abstract] [Full Text] [Related]
4. Changes in gene expression profiles of multiple myeloma cells induced by arsenic trioxide (ATO): possible mechanisms to explain ATO resistance in vivo. Zhou P, Kalakonda N, Comenzo RL. Br J Haematol; 2005 Mar 15; 128(5):636-44. PubMed ID: 15725085 [Abstract] [Full Text] [Related]
5. BH3-only proteins Noxa, Bmf, and Bim are necessary for arsenic trioxide-induced cell death in myeloma. Morales AA, Gutman D, Lee KP, Boise LH. Blood; 2008 May 15; 111(10):5152-62. PubMed ID: 18354037 [Abstract] [Full Text] [Related]
6. Arsenic trioxide-mediated growth inhibition of myeloma cells is associated with an extrinsic or intrinsic signaling pathway through activation of TRAIL or TRAIL receptor 2. Wu X, Shi J, Wu Y, Tao Y, Hou J, Meng X, Hu X, Han Y, Jiang W, Tang S, Zangari M, Tricot G, Zhan F. Cancer Biol Ther; 2010 Dec 01; 10(11):1201-14. PubMed ID: 20953137 [Abstract] [Full Text] [Related]
10. P38 MAPK inhibition enhancing ATO-induced cytotoxicity against multiple myeloma cells. Wen J, Cheng HY, Feng Y, Rice L, Liu S, Mo A, Huang J, Zu Y, Ballon DJ, Chang CC. Br J Haematol; 2008 Jan 01; 140(2):169-80. PubMed ID: 18173754 [Abstract] [Full Text] [Related]
11. Arsenic trioxide inhibits the growth of adriamycin resistant osteosarcoma cells through inducing apoptosis. Zhao H, Guo W, Peng C, Ji T, Lu X. Mol Biol Rep; 2010 Jun 01; 37(5):2509-15. PubMed ID: 19701692 [Abstract] [Full Text] [Related]
14. Quercetin decreases intracellular GSH content and potentiates the apoptotic action of the antileukemic drug arsenic trioxide in human leukemia cell lines. Ramos AM, Aller P. Biochem Pharmacol; 2008 May 15; 75(10):1912-23. PubMed ID: 18359480 [Abstract] [Full Text] [Related]
16. Arsenic trioxide uses caspase-dependent and caspase-independent death pathways in myeloma cells. McCafferty-Grad J, Bahlis NJ, Krett N, Aguilar TM, Reis I, Lee KP, Boise LH. Mol Cancer Ther; 2003 Nov 15; 2(11):1155-64. PubMed ID: 14617789 [Abstract] [Full Text] [Related]
18. Sustained activation of c-jun-N-terminal kinase plays a critical role in arsenic trioxide-induced cell apoptosis in multiple myeloma cell lines. Kajiguchi T, Yamamoto K, Iida S, Ueda R, Emi N, Naoe T. Cancer Sci; 2006 Jun 15; 97(6):540-5. PubMed ID: 16734734 [Abstract] [Full Text] [Related]